Analysis of therapeutic effect of anti-TIM-4 mAb on inflammatory disease.

2015 Fiscal Year Final Research Report

• Project/Area Number: 25461503
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Collagenous pathology/Allergology
• Research Institution: Juntendo University
• Principal Investigator: Akiba Hisaya 順天堂大学, 医学(系)研究科(研究院), 准教授 (60338316)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 自己免疫疾患 / 抗炎症作用 / アレルギー疾患 / 細胞表面分子機能

Outline of Final Research Achievements

In this study, mice were treated with anti-TIM-4 mAb during the effector phase of collagen-induced arthritis (CIA). Treatment with anti-TIM-4 mAb just before or after the onset or even at later stage of CIA significantly suppressed the development and progression by reducing pro-inflammatory cytokines in the ankle joints without affecting T or B cell responses. Consistently, clinical arthritis scores of collagen antibody-induced arthritis (CAIA) were significantly reduced in anti-TIM-4-treated mice with a concomitant decrease of pro-inflammatory cytokines in the joints. In vitro, macrophages secreted pro-inflammatory cytokines in response to TIM-4-Ig protein and LPS, which were reduced by the anti-TIM-4 mAb. The anti-TIM-4 mAb also inhibited the differentiation and bone resorbing activity of osteoclasts. The therapeutic effect of anti-TIM-4 mAb is mediated by the inhibition of pro-inflammatory cytokine production by inflammatory cells, osteoclast differentiation, and bone resorption.

Free Research Field

免疫学